近日,港股创新药企和铂医药公告披露,与日本大冢制药达成全球战略合作。协议显示,和铂医药将其用于治疗自身免疫疾病的BCMAxCD3双特异性T细胞衔接器(TCE)HBM7020在大中华地区以外的全球开发、制造及商业化权益授予大冢制药,借此获得4700万美元首付款及近期付款,叠加最高6.23亿美元的潜在里程碑付款(合计约48亿元人民币),以及未来产品销售分成。 据《华夏时报》记者统计,截至目前,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.